Patent ID: 8822487
Filing Date: 2014-09-02
Classification: A61K,Y10S

Abstract:
1. A sustained release oral dosage form, comprising: (A) an opioid agonist present as an orally therapeutically effective dose of about 8 mg to about 50 mg hydrocodone or a pharmaceutically acceptable salt thereof, or about 2.5 mg to about 800 mg oxycodone or a pharmaceutically acceptable salt thereof; (B) an opioid antagonist selected from naltrexone, naloxone, nalmephene, cyclazocine, levallorphan, and mixtures thereof, or a pharmaceutically acceptable salt thereof; and (C) a sustained release carrier incorporated into a matrix that contains said opioid agonist and said opioid antagonist; said dosage form having a ratio of said opioid antagonist to said opioid agonist that provides a combination product which is analgesically effective when the combination is administered orally, but which is aversive in physically dependent human subjects when abused at a higher dose than said therapeutically effective dose.